[
  {
    "ts": null,
    "headline": "Biogen (NasdaqGS:BIIB) Partners With City Therapeutics in US$1 Billion RNAi Therapy Deal",
    "summary": "Biogen (NasdaqGS:BIIB) recently announced a collaboration with City Therapeutics, Inc. to develop RNAi therapies for central nervous system diseases, contributing to a 6% share price increase over the past month. While this move aligns with an uptick in the broader tech sector due to policy shifts, other market responses could have influenced this rise. The announcement coincided with positive market momentum, as evident from major indexes inching upwards during this period, reflecting...",
    "url": "https://finnhub.io/api/news?id=3a516df6f6a2f4bdd4b6a35401ade22a30a38181e992382a0234a75784023aab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748366438,
      "headline": "Biogen (NasdaqGS:BIIB) Partners With City Therapeutics in US$1 Billion RNAi Therapy Deal",
      "id": 134717359,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (NasdaqGS:BIIB) recently announced a collaboration with City Therapeutics, Inc. to develop RNAi therapies for central nervous system diseases, contributing to a 6% share price increase over the past month. While this move aligns with an uptick in the broader tech sector due to policy shifts, other market responses could have influenced this rise. The announcement coincided with positive market momentum, as evident from major indexes inching upwards during this period, reflecting...",
      "url": "https://finnhub.io/api/news?id=3a516df6f6a2f4bdd4b6a35401ade22a30a38181e992382a0234a75784023aab"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. stock outperforms competitors on strong trading day",
    "summary": "Biogen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=43e70539a4e378ea3bd98a4775e980cbf637a587fbfd59fb8f9a68edd5ed7700",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748365740,
      "headline": "Biogen Inc. stock outperforms competitors on strong trading day",
      "id": 134733330,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=43e70539a4e378ea3bd98a4775e980cbf637a587fbfd59fb8f9a68edd5ed7700"
    }
  },
  {
    "ts": null,
    "headline": "Biogen strikes RNAi deal with City; Aurion withdraws IPO",
    "summary": "City will receive $46 million from Biogen under the alliance. Elsewhere, Angelini Pharma licensed a rare disease therapy and the FDA refused to review a Savara lung drug.",
    "url": "https://finnhub.io/api/news?id=cd21c55484ebafe468cda9858349ebebfc8492481f352b5cad67683d3ec7b474",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748346788,
      "headline": "Biogen strikes RNAi deal with City; Aurion withdraws IPO",
      "id": 134717361,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "City will receive $46 million from Biogen under the alliance. Elsewhere, Angelini Pharma licensed a rare disease therapy and the FDA refused to review a Savara lung drug.",
      "url": "https://finnhub.io/api/news?id=cd21c55484ebafe468cda9858349ebebfc8492481f352b5cad67683d3ec7b474"
    }
  },
  {
    "ts": null,
    "headline": "Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies",
    "summary": "Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development expertiseCAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced a strategic collaboration to develop select novel RNAi therapies. Through the collaboration, City Therapeutics will leverage its next-",
    "url": "https://finnhub.io/api/news?id=03dca823c5463f9f58641193c57453a1944a42631a20b86d87eb10705cd334d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748345400,
      "headline": "Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies",
      "id": 134717363,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development expertiseCAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced a strategic collaboration to develop select novel RNAi therapies. Through the collaboration, City Therapeutics will leverage its next-",
      "url": "https://finnhub.io/api/news?id=03dca823c5463f9f58641193c57453a1944a42631a20b86d87eb10705cd334d5"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. and City Therapeutics, Inc. Announce Strategic Research Collaboration to Develop Select Novel Rnai-Based Therapies",
    "summary": "Biogen Inc. and City Therapeutics, Inc. announced a strategic collaboration to develop select novel RNAi therapies. Through the collaboration, City Therapeutics will leverage its next-generation RNAi...",
    "url": "https://finnhub.io/api/news?id=f07b8686f8311dee720d196e8677ec9f7315db42f5258960e4751dbdcc79e679",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748336764,
      "headline": "Biogen Inc. and City Therapeutics, Inc. Announce Strategic Research Collaboration to Develop Select Novel Rnai-Based Therapies",
      "id": 134708430,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Biogen Inc. and City Therapeutics, Inc. announced a strategic collaboration to develop select novel RNAi therapies. Through the collaboration, City Therapeutics will leverage its next-generation RNAi...",
      "url": "https://finnhub.io/api/news?id=f07b8686f8311dee720d196e8677ec9f7315db42f5258960e4751dbdcc79e679"
    }
  },
  {
    "ts": null,
    "headline": "Biogen to Pay $46M in RNAi-Development Collaboration",
    "summary": "Biogen to Pay $46M in RNAi-Development Collaboration",
    "url": "https://finnhub.io/api/news?id=04774730757f1fa40e6bfb98d905333f1c463c975d55eb867abca3d03244ac7e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748333760,
      "headline": "Biogen to Pay $46M in RNAi-Development Collaboration",
      "id": 134733331,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen to Pay $46M in RNAi-Development Collaboration",
      "url": "https://finnhub.io/api/news?id=04774730757f1fa40e6bfb98d905333f1c463c975d55eb867abca3d03244ac7e"
    }
  }
]